Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.

Mario Karolyi Erich PawelkaTheresa MaderSara OmidHasan KelaniSarah ElyBernd JilmaSebastian BaumgartnerHermann LaferlClemens OttMarianna TraugottMichael TurnerTamara SeitzChristoph WenischAlexander Zoufaly

Published in: Wiener klinische Wochenschrift (2020)

No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV/RTV despite having similar patient groups, perhaps due to early initiation of treatment.

Keyphrases

end stage renal disease
case report
cardiovascular events
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
sars cov
risk factors
prognostic factors
peritoneal dialysis
early onset
cardiovascular disease
coronary artery disease
adverse drug
combination therapy
antiretroviral therapy